The £7.9 Billion Oncology Gamble: Why GSK’s Nuvalent Acquisition Could Redefine Its Future
The agreement values Nuvalent at approximately $124 per share, representing a premium of around 40 per cent over its previous market valuation. In one of the most significant pharmaceutical transactions…